Skip to content
Review Open access

Spatial determinants of pathological complete response and residual disease after neoadjuvant therapy in breast cancer

Oct 2026 · Translational Oncology · Vol 74 · 0 citations · 115 references
Medicine

Abstract

Highlights • Spatial immune architecture adds information beyond immune-cell abundance.• CD8-tumor proximity and TLS quality are linked to neoadjuvant response.• Stromal, vascular, and metabolic barriers may preserve resistant regions.• Treatment reshapes spatial ecosystems before response endpoints emerge.• Residual disease is a treatment-selected ecosystem with prognostic value.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.